DUXAP8 and hepatocellular carcinoma: Among them, DUXAP8 has been reported to mediate the malignant phenotype and chemoresistance of HCC through m6A modification (Liu et al., 2021), and can induce resistance to poly ADP-ribose polymerase (PARP) inhibitors in HCC by upregulating FOXM1 (Hu et al., 2020).